Success of the capital increase with pre-emptive subscription rights

€7.3 million raised to finance the Prima System PRIMAvera pivotal study - Seite 3

(2) Non-voting treasury shares held by the Company at 30 June 2020.

SETTLEMENT AND DELIVERY OF NEW SHARES

When the settlement and delivery of the Capital Increase is completed, the Company’s share capital will have been increased by €881,095.14 and will therefore total €2,505,619.26, divided into 41,760,321 shares with a nominal value of €0.06 each.

The issue of the New Shares, settlement and delivery and admission to trading on the Euronext Growth Paris market will take place on 8 July 2020. As from 1 January 2020, the New Shares will carry dividend rights and entitle their holders to all distributions the Company makes.

The New Shares will be immediately deemed identical to the Company’s existing shares already traded on the Euronext Growth Paris market and, as from their issue date, will be negotiable on the same listing line (ISIN: FR0011950641).

The right to exercise transferable securities conferring access to equity will resume on 8 July 2020.

PROSPECTUS

It should be noted that in accordance with Article L.411-2 of the French Monetary and Financial Code (Code monétaire et financier) and Article 211-2 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers – “AMF”), no prospectus for the Capital Increase was submitted to the AMF for approval because the total amount of the offering, calculated over a twelve-month period, did not exceed €8,000,000.

SHARE CODES

Name: Pixium Vision
ISIN code: FR0011950641
Mnemonic: ALPIX
ICB Classification : 4535 Medical Equipment
Listing venue: Euronext Growth Paris
LEI code: 96950046OPLRLKKEOO08

FINANCIAL INTERMEDIARY

Bryan, Garnier & Co, acting as Sole Manager and Bookrunner.

Contacts

Pixium Vision Guillaume Renondin Chief Financial Officer [e-mail] [phone]

Media Relations LifeSci Advisors Sophie Baumont [e-mail] [phone]

Investor Relations LifeSci Advisors Guillaume van Renterghem [e-mail] [phone]

ABOUT PIXIUM VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems require a surgical procedure and a rehabilitation period.